AbbVie Analyst Price Targets - Benzinga

AbbVie Inc

ABBVNYSE

Trade with Public

Trade with Public

$259.66

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 배당금 비교 옵션 주식 보고서

AbbVie Analyst Price Targets

Wall Street analyst price targets and consensus rating for AbbVie (ABBV).

Price Target Range — 8 Quarters

Analyst Consensus — 25 Analysts

21Buy

4Hold

Consensus RatingBuy# Analysts25Avg. Consensus PT$263Upside to Avg. PT+1.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 20, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$298→$303
Aug 17, 2026	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$295→$300
Aug 13, 2026	Wolfe Research	Alexandria Hammond	Upgrade	Peer Perform→Outperform	$300
Aug 11, 2026	BNP Paribas	Navann Ty	PT Raise	Neutral	$218→$247
Aug 10, 2026	Evercore ISI Group	Gavin Clark-Gartner	PT Raise	Outperform	$246→$260
Aug 6, 2026	Berenberg	Luisa Hector	Maintained	Buy	$275
Aug 5, 2026	Erste Group	Hans Engel	Upgrade	Hold→Buy	—
Aug 4, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$261→$288
Aug 3, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$278→$296
Aug 3, 2026	Canaccord Genuity	Gary Nachman	PT Raise	Buy	$282→$290
Aug 3, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$265→$285
Jul 31, 2026	TD Cowen	Steve Scala	Maintained	Buy	$280
Jul 31, 2026	William Blair	Matt Phipps	Maintained	Buy	—
Jul 29, 2026	Barclays	Emily Field	PT Raise	Overweight	$275→$300
Jul 22, 2026	Canaccord Genuity	Gary Nachman	PT Raise	Buy	$273→$282
Jul 15, 2026	Citigroup	Geoff Meacham	PT Raise	Neutral	$230→$260
Jul 13, 2026	UBS	Michael Yee	PT Raise	Neutral	$230→$260
Jul 13, 2026	BMO Capital	Evan David Seigerman	PT Raise	Outperform	$258→$300
Jul 10, 2026	B of A Securities	Geoff Meacham	PT Raise	Buy	$234→$276
Jul 10, 2026	RBC Capital	Trung Huynh	PT Raise	Outperform	$260→$280

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Maintains Overweight on AbbVie, Raises Price Target to $303

Piper Sandler analyst David Amsellem maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $298 to $303.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on AbbVie, Raises Price Target to $300

Wells Fargo analyst Mohit Bansal maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $295 to $300.

Benzinga Newsdesk

PRO
Wolfe Research Upgrades AbbVie to Outperform, Announces $300 Price Target

Wolfe Research analyst Alexandria Hammond upgrades AbbVie (NYSE:ABBV) from Peer Perform to Outperform and announces $300 price target.

Benzinga Newsdesk

PRO
BNP Paribas Maintains Neutral on AbbVie, Raises Price Target to $247

BNP Paribas analyst Navann Ty maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $218 to $247.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on AbbVie, Raises Price Target to $260

Evercore ISI Group analyst Gavin Clark-Gartner maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $246 to $260.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on AbbVie, Raises Price Target to $288

Guggenheim analyst Vamil Divan maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $261 to $288.

Benzinga Newsdesk